Publication details

Sarilumab for non-infectious uveitis (SARILNIU): Results from the phase 2 SATURN study

Authors

HEISSIGEROVÁ Jaroslava KARKANOVÁ Michala ŘÍHOVÁ Eva O. SATURN STUDY 

Year of publication 2016
Type Conference abstract
Citation
Description Interleukin6 (IL6) and its soluble receptor are detected in the vitreous and aqueous humors of patients with uveitis. A phase 2 study was conducted to evaluate the efficacy and safety of sarilumab, an investigational human antiIL6 receptor monoclonal antibody, in patients with posterior segment noninfectious uveitis (NIU). Patients were enrolled in investigative sites across the EU and USA.

You are running an old browser version. We recommend updating your browser to its latest version.

More info